These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 23523405)

  • 21. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of measles, mumps, rubella, and varicella susceptibility among health science students in a University in India.
    Arunkumar G; Vandana KE; Sathiakumar N
    Am J Ind Med; 2013 Jan; 56(1):58-64. PubMed ID: 22467356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The prevalence of measles, rubella, mumps and chickenpox antibodies in a population of health care workers].
    Oliveira J; da Cunha S; Côrte-Real R; Sampaio L; Dais N; Meliço-Silvestre A
    Acta Med Port; 1995 Apr; 8(4):206-16. PubMed ID: 7625214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S; Feyssaguet M; Povey M; Di Paolo E
    Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5-6 years.
    Nakayama T; Kawamura A; Sogawa Y; Sakakibara S; Nakatsu T; Kimata M; Oe K
    J Infect Chemother; 2024 Dec; 30(12):1289-1294. PubMed ID: 38906375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced Antibody Response to Infant Measles Vaccination: Effects Based on Type and Timing of the First Vaccine Dose Persist After the Second Dose.
    Carazo Perez S; De Serres G; Bureau A; Skowronski DM
    Clin Infect Dis; 2017 Oct; 65(7):1094-1102. PubMed ID: 28595358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibodies against vaccine-preventable diseases in pregnant women and their offspring. Measles, mumps, rubella, poliomyelitis, and varicella].
    Sauerbrei A; Prager J; Bischoff A; Wutzler P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2004 Jan; 47(1):10-5. PubMed ID: 15205818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
    Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of vaccine program on IgG antibody titers for measles, rubella, varicella, and mumps in young adults in Japan: Survey between 2018 and 2021.
    Miyazaki H; Yamanaka G; Furukawa K; Ichiki M
    J Infect Chemother; 2022 Oct; 28(10):1410-1414. PubMed ID: 35779802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization.
    Sato H; Albrecht P; Reynolds DW; Stagno S; Ennis FA
    Am J Dis Child; 1979 Dec; 133(12):1240-3. PubMed ID: 229727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
    Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG
    Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of measles, rubella, mumps, and varicella antibodies among healthcare workers in Japan.
    Hatakeyama S; Moriya K; Itoyama S; Nukui Y; Uchida M; Shintani Y; Morisawa Y; Kimura S
    Infect Control Hosp Epidemiol; 2004 Jul; 25(7):591-4. PubMed ID: 15301032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Susceptibility to measles, rubella and parotitis in young adults].
    Bayas JM; Vilella A; Vidal J; Nebot X; Carbó JM; Navarro G; Prat A; Asenjo MA; Salleras L
    Med Clin (Barc); 1996 Apr; 106(15):561-4. PubMed ID: 8656753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of the IgM fraction from patients' sera in general virus serology for diagnostic purposes].
    Wolff MH; Marklein G; Schneweis KE; Stifter G
    Zentralbl Bakteriol Orig A; 1974; 227(1-4):392-400. PubMed ID: 4154618
    [No Abstract]   [Full Text] [Related]  

  • 38. Rubella susceptibility predicts measles susceptibility: implications for postpartum immunization.
    Libman MD; Behr MA; Martel N; Ward BJ
    Clin Infect Dis; 2000 Dec; 31(6):1501-3. PubMed ID: 11096023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
    Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.